In Greek mythology, Scylla was a ferocious beast and Charybdiswas a monstrous whirlpool. The wily Odysseus successfully navigatedbetween these two dangers by steering closer to Scylla, thoughhe did lose a few crew members to her. In a similar manner,the astute clinician managing myocardial ischemia by using antiplatelettherapy attempts to balance coronary thrombosis, the basic causeof myocardial ischemia, against hemorrhage, the most-fearedcomplication of antiplatelet therapy. There are many pathwaysby which antiplatelet drugs may antagonize platelet activationor aggregation, all of which increase the risk of bleeding,and many of which decrease the risk . . . [Full Text of this Article]
Source Information
From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland.
This article (10.1056/NEJMe0706859) was published at www.nejm.org on November 4, 2007.
Related Letters:
Prasugrel versus Clopidogrel
Serebruany V., Pasceri V., Patti G., Di Sciascio G., von Lewinski F., Riggert J., Paulus W., Wiviott S. D., Braunwald E., Antman E. M., Bhatt D. L.
Extract |
Full Text |
PDF
N Engl J Med 2008;
358:1298-1301, Mar 20, 2008.
Correspondence
This article has been cited by other articles:
Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., Kleiman, N. S., Goodman, S. G., White, H. D., Mahaffey, K. W., Pollack, C. V. Jr., Manoukian, S. V., Widimsky, P., Chew, D. P., Cura, F., Manukov, I., Tousek, F., Jafar, M. Z., Arneja, J., Skerjanec, S., Harrington, R. A., the CHAMPION PLATFORM Investigators,
(2009). Intravenous Platelet Blockade with Cangrelor during PCI. NEJM
0: NEJMoa0908629v1-1
[Abstract][Full Text]
Momi, S., Falcinelli, E., Giannini, S., Ruggeri, L., Cecchetti, L., Corazzi, T., Libert, C., Gresele, P.
(2009). Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. JEM
206: 2365-2379
[Abstract][Full Text]
Serebruany, V., Rao, S. V., Silva, M. A., Donovan, J. L., Kannan, A. O., Makarov, L., Goto, S., Atar, D.
(2009). Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J
0: ehp434v1-ehp434
[Abstract][Full Text]
Schomig, A.
(2009). Ticagrelor -- Is There Need for a New Player in the Antiplatelet-Therapy Field?. NEJM
361: 1108-1111
[Full Text]
Bhatt, D. L.
(2009). Prasugrel in Clinical Practice. NEJM
361: 940-942
[Full Text]
Bhatt, D. L.
(2009). Tailoring Antiplatelet Therapy Based on Pharmacogenomics: How Well Do the Data Fit?. JAMA
302: 896-897
[Full Text]
Jeong, Y. H., Lee, S.-W., Choi, B.-R., Kim, I.-S., Seo, M.-K., Kwak, C. H., Hwang, J.-Y., Park, S.-W.
(2009). Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.. J Am Coll Cardiol
53: 1101-1109
[Abstract][Full Text]
Cohen, M.
(2009). Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clin Proc.
84: 149-160
[Abstract][Full Text]
Chhatriwalla, A. K., Bhatt, D. L.
(2008). Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Be Continued for More Than One Year and Preferably Indefinitely. Circ Cardiovasc Interv
1: 217-225
[Full Text]
Bhatt, D. L.
(2008). Resisting the Temptation to Oversimplify Antiplatelet Resistance. J Am Coll Cardiol Intv
1: 660-662
[Full Text]
Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K.L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., Quigley, E. M., Harrington, R. A., Bates, E. R., Bridges, C. R., Eisenberg, M. J., Ferrari, V. A., Hlatky, M. A., Kaul, S., Lindner, J. R., Moliterno, D. J., Mukherjee, D., Schofield, R. S., Rosenson, R. S., Stein, J. H., Weitz, H. H., Wesley, D. J.
(2008). ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol
52: 1502-1517
[Full Text]
Writing Committee Members, , Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K.L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., Quigley, E. M.
(2008). ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation
118: 1894-1909
[Full Text]
Bhatt, D. L.
(2008). What Makes Platelets Angry: Diabetes, Fibrinogen, Obesity, and Impaired Response to Antiplatelet Therapy?. J Am Coll Cardiol
52: 1060-1061
[Full Text]
Angiolillo, D. J., Capranzano, P., Goto, S., Aslam, M., Desai, B., Charlton, R. K., Suzuki, Y., Box, L. C., Shoemaker, S. B., Zenni, M. M., Guzman, L. A., Bass, T. A.
(2008). A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J
29: 2202-2211
[Abstract][Full Text]
Alvarez, W. Jr.
(2008). For better or for worse: The future of antiplatelet therapy. Am J Health Syst Pharm
65: 1017-1017
[Full Text]
Serebruany, V., Pasceri, V., Patti, G., Di Sciascio, G., von Lewinski, F., Riggert, J., Paulus, W., Wiviott, S. D., Braunwald, E., Antman, E. M., Bhatt, D. L.
(2008). Prasugrel versus Clopidogrel. NEJM
358: 1298-1301
[Full Text]
(2007). Prasugrel in Patients with Acute Coronary Syndromes. JWatch Oncology and Hematology
2007: 1-1
[Full Text]
Previous
